- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
JLL Releases 2021 Life Sciences Real Estate Outlook
Coupled with broader migration trends happening in the US, new upstart locations become increasingly attractive for investors, developers, tenants, and landlords.
JLL Life Sciences has released its 2021 Life Sciences Real Estate Outlook, which aims to identify the fundamental industry trends driving demand for lab space now and into the future. As core cluster markets generate outsized demand, industry growth and productivity are also being driven by the adoption of new technologies and rapid advancements in innovation.
The life sciences sector is attracting real estate capital from around the globe, with investors targeting legacy markets where industry clusters are strongest and where a density of lab properties already exist. But, strong buyer competition in key clusters, coupled with emerging growth in secondary markets, is driving investment and development activity beyond the traditional geographies.
Read more about the full report here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
